Rationale and Design of the Cardiac CARE Trial: A Randomized Trial of Troponin-Guided Neurohormonal Blockade for the Prevention of Anthracycline Cardiotoxicity.
Peter A HenriksenPeter S HallOlga OikonomidouIain R J MacphersonMorag MacleanStephanie LewisHeather McVicarsAngus BroomFiona ScottPamela McKayAnnabel BorleyClare RowntreeSimon R LordGraham CollinsJohn RadfordAmy GuppyJohn R PayneDavid E NewbyNicholas L MillsNinian N LangPublished in: Circulation. Heart failure (2022)
Cardiac CARE will examine whether cardiac biomarker monitoring identifies patients at risk of left ventricular dysfunction following anthracycline chemotherapy and whether troponin-guided treatment with combination candesartan and carvedilol therapy prevents the development of left ventricular dysfunction in these high-risk patients.
Keyphrases
- left ventricular
- hypertrophic cardiomyopathy
- healthcare
- end stage renal disease
- acute myocardial infarction
- heart failure
- cardiac resynchronization therapy
- aortic stenosis
- mitral valve
- ejection fraction
- palliative care
- left atrial
- chronic kidney disease
- quality improvement
- clinical trial
- pain management
- peritoneal dialysis
- study protocol
- prognostic factors
- coronary artery disease
- phase ii
- gene expression
- phase iii
- squamous cell carcinoma
- mesenchymal stem cells
- combination therapy
- cell therapy
- replacement therapy